CN116949176B - Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product - Google Patents
Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product Download PDFInfo
- Publication number
- CN116949176B CN116949176B CN202211455595.0A CN202211455595A CN116949176B CN 116949176 B CN116949176 B CN 116949176B CN 202211455595 A CN202211455595 A CN 202211455595A CN 116949176 B CN116949176 B CN 116949176B
- Authority
- CN
- China
- Prior art keywords
- prognosis
- mutation
- fas gene
- application
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150064015 FAS gene Proteins 0.000 title claims abstract description 43
- 238000001514 detection method Methods 0.000 title claims abstract description 38
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 title claims abstract description 36
- 238000004393 prognosis Methods 0.000 title claims abstract description 33
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 24
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title description 5
- 230000035772 mutation Effects 0.000 claims abstract description 36
- 239000000523 sample Substances 0.000 claims description 57
- 238000009396 hybridization Methods 0.000 claims description 23
- 241000796533 Arna Species 0.000 claims description 16
- 230000004083 survival effect Effects 0.000 abstract description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 12
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 11
- 230000007774 longterm Effects 0.000 abstract description 3
- 238000009098 adjuvant therapy Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 20
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000000243 solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000036210 malignancy Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000010837 poor prognosis Methods 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 239000000980 acid dye Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011470 radical surgery Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OHOQEZWSNFNUSY-UHFFFAOYSA-N Cy3-bifunctional dye zwitterion Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCN1C2=CC=C(S(O)(=O)=O)C=C2C(C)(C)C1=CC=CC(C(C1=CC(=CC=C11)S([O-])(=O)=O)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CCC1=O OHOQEZWSNFNUSY-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101001123267 Homo sapiens Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 Proteins 0.000 description 1
- 101000711577 Homo sapiens RING finger protein 122 Proteins 0.000 description 1
- 101000880385 Homo sapiens STING ER exit protein Proteins 0.000 description 1
- 101000662704 Homo sapiens Trafficking protein particle complex subunit 13 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102100029025 Probable inactive peptidyl-prolyl cis-trans isomerase-like 6 Human genes 0.000 description 1
- 102100034117 RING finger protein 122 Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037658 STING ER exit protein Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102100037452 Trafficking protein particle complex subunit 13 Human genes 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000007482 whole exome sequencing Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to an application of a reagent for detecting FAS gene mutation in preparing pancreatic duct adenocarcinoma prognosis detection products; the mutation site is selected from g.8901119C > T or/and g.89021477G > A. Compared with the prior art, the beneficial effects of the application include: based on long-term clinical and extensive case studies, the inventors of the present applicant found that mutations at two sites in the FAS gene (g.8901119c > T or/and g.89021477g > a) are closely related to prognosis of pancreatic ductal adenocarcinoma, and by detecting the mutation at these two sites in the FAS gene, prognosis of patients after radical PDAC treatment, including survival, can be predicted. The method can provide accurate guidance and clinical advice for prognosis and subsequent adjuvant treatment of pancreatic cancer patients.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of a reagent for detecting FAS gene mutation sites in preparation of pancreatic duct adenocarcinoma prognosis detection products.
Background
Pancreatic ductal adenocarcinoma (pancreatic ductal adenocarcinoma, PDAC) accounts for more than 90% of pancreatic malignancies (pancreatic cancer), a tumor of the digestive system with high malignancy and poor prognosis, called "king in cancer", with a survival rate of less than 10% in 5 years. There is currently no effective treatment and means to predict disease progression. The method can evaluate the PDAC treatment effect, predict the disease progress and the prognosis situation in time and has great significance for the clinical treatment of PDAC and the social hygiene and economy.
The pancreatic duct adenocarcinoma has high malignancy degree and poor prognosis, and the traditional CT, nuclear magnetism, tumor marker CA19-9 and the like can not accurately know the disease progress and prognosis, so that the prognosis can not be predicted in advance, the difficulty is brought to clinical diagnosis and treatment, and the risk is increased.
In view of this, the present application is specifically proposed.
Disclosure of Invention
One of the purposes of the embodiments of the present application includes the use of reagents for detecting the appropriate mutation sites of the FAS gene in the preparation of a pancreatic ductal adenocarcinoma prognostic test product, which provides an effective means for prognosis of pancreatic ductal adenocarcinoma.
In a first aspect of the present application, there is provided the use of a reagent for detecting FAS gene mutation in the preparation of a pancreatic ductal adenocarcinoma prognostic assay product;
the mutation site is selected from g.8901119C > T or/and g.89021477G > A.
In some embodiments of the present application, the reagent comprises a specific hybridization probe.
In some embodiments of the present application, the specific hybridization probe targets an aRNA that binds to the FAS gene.
In some embodiments of the present application, the sample detected is a tissue or a cell.
In a second aspect of the present application there is provided a pancreatic ductal adenocarcinoma prognosis kit comprising the reagents defined in the first aspect.
In some embodiments of the present application, the kit comprises a detection chip on which detection probes are immobilized, the detection probes comprising specific hybridization probes as defined in the first aspect.
In some embodiments of the present application, the kit further comprises one or more of a sample RNA preservation reagent, an RNA extraction reagent, an RNA amplification reagent, a nucleic acid dye, and a hybridization reagent.
In a third aspect of the present application, there is provided a method for detecting FAS gene for non-diagnostic purposes, the method comprising the steps of:
obtaining aRNA of a sample;
fluorescence labeling the aRNA;
and (3) carrying out hybridization reaction on the aRNA marked by fluorescence and the detection chip defined in the second aspect, detecting the fluorescence intensity of the detection chip after the hybridization reaction, and judging the mutation condition of the FAS gene of the sample according to the detection result.
In some embodiments of the present application, determining the mutation status of the FAS gene of the sample according to the detection result includes:
under the condition that fluorescence is not detected on a detection chip after hybridization reaction, the FAS gene of the sample does not exist g.8901119C > T and g.89021477G > A;
under the condition that fluorescence is detected on a detection chip after hybridization reaction, g.8901119C > T or/and g.89021477G > A exist in the FAS gene of the sample.
Compared with the prior art, the beneficial effects of the application include:
based on long-term clinical and extensive case studies, the inventors of the present applicant found that mutations at two sites in the FAS gene (g.8901119c > T or/and g.89021477G > a) are closely related to prognosis of pancreatic ductal adenocarcinoma, and by detecting the mutation at these two sites in the FAS gene, prognosis of patients after radical PDAC treatment, including survival, can be predicted. The method can provide accurate guidance and clinical advice for prognosis and subsequent adjuvant treatment of pancreatic cancer patients.
Detailed Description
The present invention will be described in further detail with reference to embodiments and examples. It should be understood that these embodiments and examples are provided solely for the purpose of illustrating the invention and are not intended to limit the scope of the invention in order that the present disclosure may be more thorough and complete. It will also be appreciated that the present invention may be embodied in many different forms and is not limited to the embodiments and examples described herein, but may be modified or altered by those skilled in the art without departing from the spirit of the invention, and equivalents thereof fall within the scope of the present application. Furthermore, in the following description, numerous specific details are set forth in order to provide a more thorough understanding of the invention, it being understood that the invention may be practiced without one or more of these details.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing the embodiments and examples only and is not intended to be limiting of the invention.
Terminology
Unless otherwise indicated or contradicted, terms or phrases used herein have the following meanings:
the term "and/or," "and/or," as used herein, includes any one of two or more of the listed items in relation to each other, as well as any and all combinations of the listed items in relation to each other, including any two of the listed items in relation to each other, any more of the listed items in relation to each other, or all combinations of the listed items in relation to each other. It should be noted that, when at least three items are connected by a combination of at least two conjunctions selected from "and/or", "or/and", "and/or", it should be understood that, in this application, the technical solutions certainly include technical solutions that all use "logical and" connection, and also certainly include technical solutions that all use "logical or" connection. For example, "a and/or B" includes three parallel schemes A, B and a+b. For another example, the technical schemes of "a, and/or B, and/or C, and/or D" include any one of A, B, C, D (i.e., the technical scheme of "logical or" connection), and also include any and all combinations of A, B, C, D, i.e., any two or three of A, B, C, D, and also include four combinations of A, B, C, D (i.e., the technical scheme of "logical and" connection).
The terms "plurality", "plural", "multiple", and the like in the present invention refer to, unless otherwise specified, an index of 2 or more in number. For example, "one or more" means one kind or two or more kinds.
As used herein, "a combination thereof," "any combination thereof," and the like include all suitable combinations of any two or more of the listed items.
The "suitable" in the "suitable combination manner", "suitable manner", "any suitable manner" and the like herein refers to the fact that the technical scheme of the present invention can be implemented, the technical problem of the present invention is solved, and the technical effect expected by the present invention is achieved.
Herein, "preferred", "better", "preferred" are merely to describe better embodiments or examples, and it should be understood that they do not limit the scope of the invention.
In the present invention, "further", "still further", "particularly" and the like are used for descriptive purposes to indicate differences in content but should not be construed as limiting the scope of the invention.
In the present invention, "optional" means optional or not, that is, means any one selected from two parallel schemes of "with" or "without". If multiple "alternatives" occur in a technical solution, if no particular description exists and there is no contradiction or mutual constraint, then each "alternative" is independent.
In the present invention, the terms "first", "second", "third", "fourth", etc. are used for descriptive purposes only and are not to be construed as indicating or implying a relative importance or quantity, nor as implying an importance or quantity of a technical feature being indicated. Moreover, the terms "first," "second," "third," "fourth," and the like are used for non-exhaustive list description purposes only, and are not to be construed as limiting the number of closed forms.
In the invention, the technical characteristics described in an open mode comprise a closed technical scheme composed of the listed characteristics and also comprise an open technical scheme comprising the listed characteristics.
In the present invention, a numerical range (i.e., a numerical range) is referred to, and optional numerical distributions are considered to be continuous within the numerical range and include two numerical endpoints (i.e., a minimum value and a maximum value) of the numerical range and each numerical value between the two numerical endpoints unless otherwise specified. Unless otherwise indicated, when a numerical range merely refers to integers within the numerical range, both end integers of the numerical range are included, as well as each integer between the two ends, herein, each integer is recited directly, such as t is an integer selected from 1-10, and t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10. Further, when a plurality of range description features or characteristics are provided, these ranges may be combined. In other words, unless otherwise indicated, the ranges disclosed herein are to be understood to include any and all subranges subsumed therein.
The temperature parameter in the present invention is not particularly limited, and may be a constant temperature treatment or may vary within a predetermined temperature range. It should be appreciated that the constant temperature process described allows the temperature to fluctuate within the accuracy of the instrument control. Allows for fluctuations within a range such as + -5 ℃, + -4 ℃, + -3 ℃, + -2 ℃, + -1 ℃.
In the present invention,% (w/w) and wt% each represent weight percent,% (v/v) represents volume percent, and% (w/v) represents mass volume percent.
All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Unless otherwise contradicted by purpose and/or technical solution of the present application, the cited documents related to the present invention are incorporated by reference in their entirety for all purposes. When reference is made to a cited document in the present invention, the definitions of the relevant technical features, terms, nouns, phrases, etc. in the cited document are also incorporated. In the case of the cited documents, examples and preferred modes of the cited relevant technical features are incorporated into the present application by reference, but are not limited to the embodiments that can be implemented. It should be understood that when a reference is made to the description herein, it is intended to control or adapt the present application in light of the description herein.
Gene probe: the method is characterized in that a large number of probe molecules are immobilized on a support and hybridized with labeled sample molecules, the hybridization signal intensity of each probe molecule is detected, so that the number and sequence information of the sample molecules are obtained, and the batch detection of multiple genes is carried out.
Gene probes are applied to accurate gene information interpretation of tumor specimens at present, but no gene probes for evaluating and predicting PDAC disease prognosis conditions exist at present, so that clinicians cannot know the full-scale and prognosis conditions of PDAC disease from the disease sources of gene mutation. There is currently no genetic probe for pancreatic ductal adenocarcinoma or any pancreatic malignancy.
First aspect of the present application
The application provides application of a reagent for detecting FAS gene mutation in preparing pancreatic duct adenocarcinoma prognosis detection products;
the mutation site is selected from g.8901119C > T or/and g.89021477G > A.
In the present application, the FAS gene mutation means a mutation occurring in a wild-type FAS gene.
It should be noted that, the above-mentioned mutation sites are all referred to the content recorded in the NCBI database, and those skilled in the art should understand that, due to the update of the database or the difference between the databases, the shown mutation sites may be slightly different or changed, and these differences or changes may be found by taking the content in the database as a standard, and these differences or changes are also included in the protection scope of the present application. Moreover, it will be appreciated by those skilled in the art that the FAS gene referred to in this application is based on a wild-type FAS gene in the human genome, but when the wild-type FAS gene is present in other species, the sequence may be different, and the wild-type FAS gene of the species may be aligned with the wild-type FAS gene in the human genome to obtain the corresponding position in the wild-type FAS gene of the species.
It will be appreciated that the means of detection are not limited under conditions capable of detecting the FAS gene mutation, including, but not limited to, at least one of antibodies, probes, primers, and mass spectrometry detection reagents specific for at least one of the gene mutation or the polypeptide encoded thereby. For example, the presence or absence of such mutations in a test sample can be detected by the specific binding of an antibody that specifically recognizes the polypeptide to the polypeptide, i.e., by the interaction of a specific antibody with an antigen; the existence of the nucleic acid or the gene mutation can also be identified by designing a probe which specifically recognizes the gene mutation in advance and carrying out complementary pairing on the probe and the nucleic acid fragment where the nucleic acid or the gene mutation site is positioned; specific primers for amplifying the exons where the above-mentioned genetic mutations are located can also be designed, and then the presence or absence of the above-mentioned genetic mutations can be determined by gene amplification and sequencing; the presence or absence of the polypeptide expressed by the mutation can also be determined by mass spectrometry to detect the m/z of the polypeptide. At least one of the antibodies, probes, primers and mass spectrometry detection reagents according to the specific embodiments of the present application can specifically and highly sensitively screen out the aforementioned gene mutations or the aforementioned polypeptides, thereby specifically and highly sensitively predicting the prognosis of pancreatic ductal adenocarcinoma.
Optionally, the reagent comprises a specific hybridization probe.
Alternatively, the specific hybridization probe targets an aRNA that binds to the FAS gene.
Alternatively, the sample detected is a tissue or a cell.
Second aspect of the present application
The present application provides a pancreatic ductal adenocarcinoma prognosis kit comprising the reagents defined in the first aspect.
Optionally, the kit comprises a detection chip on which detection probes are immobilized, the detection probes comprising specific hybridization probes as defined in the first aspect.
Optionally, the kit further comprises one or more of sample RNA preservation reagents, RNA extraction reagents, RNA amplification reagents, nucleic acid dyes, and hybridization reagents.
Third aspect of the present application
The application provides a detection method of FAS genes for non-diagnostic purposes, which comprises the following steps:
obtaining aRNA of a sample;
fluorescence labeling the aRNA;
and (3) carrying out hybridization reaction on the aRNA marked by fluorescence and the detection chip defined in the second aspect, detecting the fluorescence intensity of the detection chip after the hybridization reaction, and judging the mutation condition of the FAS gene of the sample according to the detection result.
Optionally, determining the mutation status of the FAS gene of the sample according to the detection result includes:
under the condition that fluorescence is not detected on a detection chip after hybridization reaction, the FAS gene of the sample does not exist g.8901119C > T and g.89021477G > A;
under the condition that fluorescence is detected on a detection chip after hybridization reaction, g.8901119C > T or/and g.89021477G > A exist in the FAS gene of the sample.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Embodiments of the present invention will be described in detail below with reference to examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples, in which specific conditions are not noted, are preferably referred to the guidelines given in the present invention, and may be according to the experimental manual or conventional conditions in the art, the conditions suggested by the manufacturer, or the experimental methods known in the art.
In the specific examples described below, the measurement parameters relating to the raw material components, unless otherwise specified, may have fine deviations within the accuracy of weighing. Temperature and time parameters are involved, allowing acceptable deviations from instrument testing accuracy or operational accuracy.
Pancreatic Ductal Adenocarcinoma (PDAC) is a malignancy with high malignancy, poor prognosis, high recurrence-metastasis rate, and less than 10% of 5-year survival, and is called "king in cancer". At present, no effective treatment means exists clinically, and no method capable of specifically evaluating the disease progress and accurately predicting the prognosis of a patient exists. The research work of the application relates to tumor specimen sequencing and long-term postoperative follow-up visit are carried out on 315 patients treated by pancreatic cancer radical surgery in Beijing co-ordination hospitals in 2008 to 2015, FAS gene mutation is found to be positively correlated with prognosis of PDAC patients, and the higher the FAS gene mutation level is, the worse the prognosis of the PDAC patients is, and the shorter the postoperative survival time is.
The application comprises the following steps:
1. in the research work, clinical test indexes and operation conditions of all patients treated by the pancreatic cancer radical operation in 2008-2015 are analyzed in detail, clinical baseline data (sex, age, disease course, symptoms, past history, personal history, family history, preoperative physical examination and the like) are screened, no obvious statistical difference exists in the preoperative test (blood convention, liver and kidney functions, blood coagulation, tumor markers (including CA 19-9) and the like), no obvious statistical difference exists in the preoperative examination (tumor size, part and the like), the operation is radical excision (including pancreas-duodenal excision, pancreas-tail-spleen excision and the like), the pathological incisional edge is negative, the pathological diagnosis is pancreatic duct adenocarcinoma, and the postoperative radiotherapy and chemotherapy treatment scheme does not have obvious statistical difference in 315, and the examples are common.
2. The 315 patients are followed up to obtain detailed and accurate prognosis data such as total postoperative survival time, disease-free survival time (no recurrence and metastasis), death time and the like.
3. The tumor samples of the 315 patients were subjected to whole genome sequencing analysis (sequencing depth 40×) and whole exome sequencing analysis (sequencing depth 200×) to obtain over 2.7 ten thousand genes with effective mutation. The applicant team then performed detailed, thorough, and detailed bioinformatic analyses:
(1) Mutation ratio sequencing and difference sequencing are respectively carried out on 2.7 ten thousand genes with effective mutation according to the radical post-operation survival time length of a patient, and 2414 genes with clinical significance and mutation statistics difference (within the top 10% of the ranking in the ratio sequencing or the difference sequencing) are screened according to the original clinical phenotype (clinical significance), mutation phenotype and mutation site of each gene.
(2) The above 2414 first screened important genes are subjected to bioinformatics analysis and signal path analysis by a bioinformatics analysis platform such as IPA, KEGG, GO, STRING, and 9 important signal paths are sorted and screened by enriching the mutation ratio sum and the difference sum of all genes in each signal path.
(3) And (3) carrying out total evaluation and scoring on the analysis results and clinical effects and signal path values of the genes in the aspects of pancreatic origin, tumor (tumor pathological characteristics such as adenocarcinoma, squamous carcinoma, adenosquamous carcinoma and the like), endocrine, immunity and the like, sorting according to the obtained scores, and screening to obtain 97 key genes.
(4) The 97 key genes are made into initial gene probes, 315 tumor specimens are subjected to sequence sequencing with the depth of 1000 x, and the obtained sequencing result is refined again, so that the analysis process is repeated.
(5) Finally, integrating information such as clinical characterization, gene functions, bioinformatics, basic medicine and the like, and finally finding out all factors such as the mutation of the FAS gene (g.8901119C > T and g.89021477G > A) to have a high-specificity prediction effect on the prognosis survival period of a patient after the radical PDAC treatment according to the biological effect of each gene, the positive and negative values of the correlation between the gene mutation and the survival period of the patient, the position and the connection effect of the gene mutation in a key signal path, the multiple ranking order of the actual mutation difference, the difference ranking order of the actual mutation difference and the like: as long as at least one of the two mutation sites of the FAS gene shows positive detection results, the survival time of the radical cure post-operation survival time does not exceed 24 months.
Of all 315 PDAC tumor specimens involved in sequencing, 22 patients detected FAS gene mutations (sensitivity 6.98%), with a total survival of 4 to 18 months, a median survival of 11 months, an ultrashort survival (postoperative survival < 12 months) of 12 patients (54.5%), and a short survival (postoperative survival < 15 months) of 20 patients (90.9% of specificity).
The FAS mutation sites in 22 patients were mainly focused on the following sites:
TABLE 1
4. Based on the clinical data and the biological informatics analysis detection results, the applicant team designs a FAS gene mutation detection probe which is a PDAC specific prognosis detection probe. The specific sequence is as follows:
TABLE 2
5. Gene probes were prepared from the above sequences, and tumor tissue specimens of PDAC patients who underwent radical surgery treatment were examined for 69 other patients (not included in the 315 patients and not statistically different from clinical baseline data), comprising the steps of:
(1) And immersing the pancreatic cancer tissue specimens collected in the operation and surrounding normal pancreatic tissues in an RNA Later for normal temperature preservation.
(2) Total mRNA was extracted using Trizol method: the tissue specimen pieces were placed in a 10ml centrifuge tube, added with about 10 volumes of Trizol, placed on ice, homogenized well and centrifuged briefly. The homogenate was then aspirated 5-10 times with a syringe 0.9mm in diameter until complete homogenization, and well lysed in Trizol reagent. Then adding 1/5 volume of chloroform into the homogenate, shaking and mixing thoroughly, standing on ice for 10min until the two phases are separated, centrifuging at maximum speed for 15min, sucking the supernatant to a new 1.5ml centrifuge tube, adding 70% ethanol with equal volume, and mixing repeatedly. Then, 700. Mu.l of the solution RW1 was added to the centrifugal purification column, and the mixture was centrifuged at maximum speed for 15s. The column was placed in a new collection tube and 500. Mu.l of RPE solution was added and centrifuged at maximum speed for 15s. Then, 500. Mu.l of RPE solution was added, the mixture was centrifuged at maximum speed for 2min, the filtrate was discarded, and the mixture was centrifuged at maximum speed for 1min, and the filtrate was discarded. The column was placed in a new sample collection tube, 100. Mu.l DEPC water was added, centrifuged at maximum speed for 1min, and the two filtrates were combined. Adding 2.5 times volume of absolute ethanol and 1/10 volume of 3M sodium acetate (pH 5.2, prepared by DEPC water), standing at room temperature for 30min or precipitating at-20deg.C for longer time, standing at 4deg.C for 13, 400rpm×15min, discarding supernatant, adding 1ml of 75% ethanol for resuspension, 7500rpm×5min, discarding supernatant, repeating once, and air drying at room temperature.
Adding proper amount of DEPC water to dissolve precipitate, and determining concentration and total amount of RNA sample, wherein when TE buffer/EB buffer is used as blank control and diluent, the A260/A280 ratio of RNA sample should be 1.8-2.0.
(3) RNA micro-amplification, and cDNA synthesis through reverse transcription: taking 0.5-2ug of total RNA, adding T7 Oligo (dT) primer and water without Nuclease-pollution, denaturing at 70 ℃ for 5min, cooling on ice for 5min, adding 10 x first strand synthesis buffer, ribonucleoase inhibitor, dNTP and reverse transcriptase mixed solution, and preserving heat at 42 ℃ for 2h. Mu.l of the cDNA sample was taken, and then, water free of nucleic acid-contamination, 10 Xsecond strand synthesis buffer, dNTP Mix, DNA Polymerase, RNase H were added thereto, and incubated at 16℃for 2 hours. The Cartridge was placed in a 2ml collection tube, 100. Mu.l cDNA Binding was added and allowed to stand at room temperature for 5min. After adding 250 mu l cDNA Binding Buffer to the obtained cDNA sample and shaking and mixing, the cDNA sample was added to the Cartridge, centrifuged at 10000 Xg for 1min, the filtrate was discarded, and the Filter Cartridge was returned to a 2ml recovery tube. Then 650 mu l cDNA Wash Buffer is added into the Filter Cartridge, 10000 Xg is centrifuged for 1min, the filtrate is discarded, and the Filter Cartridge is centrifuged for 1min, so that the Filter Cartridge is free of residual ethanol, and the Cartridge is transferred into a new collection tube. 50 μl of preheated Nuclear-Free Water was added, left at room temperature for 2min, centrifuged at 10000 Xg for 90s, and repeated.
(4) Amplified to aRNA and purified: 14. Mu.l of the cDNA sample was taken, and ATP, CTP, GTPmix, UTP solution, aaUTP, T7X Reaction Buffer, T7 Enzyme Mix were added thereto, incubated at 37℃for 14 hours, and RNase-free water was added thereto to adjust the volume to 100. Mu.l. Add 350. Mu. l aRNA Binding Buffer and mix well. Then 250 μl of absolute ethanol is added and mixed well. Then adding the mixture into the prepared Filter Cartridge, centrifuging the mixture for 1min at 10000 Xg, discarding the filtrate, and placing the Filter Cartridge into a 2ml recovery tube. Adding 650 mu l aRNA Wash Buffer to Filter Cartridge, centrifuging 10000 Xg for 1min, discarding the filtrate, centrifuging for 1min again, leaving Filter Cartridge free of residual ethanol, and transferring the Cartridge to a new collection tube. 50 μl of preheated Nuclear-Free Water was added, left at room temperature for 2min, centrifuged at 10000 Xg for 90s, and repeated. The aRNA concentration and yield were measured.
(5) Labeling with Cy3 fluorescent molecules: 15-20. Mu.g of aRNA was dried in vacuo and redissolved in 9. Mu. l Coupling Buffer, and 11. Mu.l of mono-active Cy3 dye was added, mixed well and allowed to stand at room temperature in the dark for 30min. 4.5. Mu.l of hydroxyamine was added, and the mixture was left to stand in the dark for 15 minutes after being mixed uniformly. Nuclease-free water was added to a volume of 30. Mu.l, 105. Mu. l aRNA Binding Buffer was added, mixed well, 75. Mu.l absolute ethanol was added, mixed well and transferred to aRNA Filter Cartridge purification column. Centrifugation was performed for 10000 g.times.1 min, after addition of Wash Buffer, re-centrifugation was performed, and then Nuclear-free water was added for 20. Mu.l, centrifugation was performed, and re-centrifugation was performed. The two products were combined and the total amount of recovered product was obtained by spectrophotometric measurement of A260/A280/A550/A650.
(6) Hybridization of the probe: taking 5 mug of the marked sample, vacuum-pumping, re-dissolving in about 3 mug of nucleic-free water, carrying out water bath for 5min at 95 ℃, adding 27 mug l Operon hybridization Buffer on ice for 1min, fully mixing, centrifuging, and carrying out hybridization reaction with a detection chip of the application, wherein the detection chip is a sample application method hybridization chip formed by combining FAS oligonucleotide probe arrays.
(7) Scanning and data processing: scanning was performed using a scanner (LuxScan, beijing bloo), after which the image was converted into a digital signal based on fluorescence intensity (GenePix), followed by data analysis and processing.
After correction and accounting of the data of the experimental group and the control group, 4 FAS gene mutation patients (2 of which are detected by the detection probes shown by SEQ ID No.1 and 2 of which are detected by the detection probes shown by SEQ ID No. 2) are detected, and the survival time after radical treatment is respectively 5 months, 11 months, 12 months and 13 months, so that the specificity of the FAS probes in the application for predicting the pancreatic cancer radical treatment short survival time (the survival time after the operation is less than 15 months) reaches 100%, and the FAS mutation probes are fully shown to be capable of predicting the survival condition of the patients after the PDAC radical treatment: FAS mutations are positively correlated with short patient survival and poor prognosis following radical PDAC surgery.
In the earlier study, 97 key genes are obtained through screening, but through full analysis and screening of the study, other than FAS and other 31 core factors which are closely related to prognosis conditions after radical pancreatic cancer treatment, 65 genes are related to pancreatic cancer, such as TRAPPC13, RNF122, PPIL6, CXorf56 and the like, but the prediction effect of statistical difference cannot be generated on the prognosis judgment of pancreatic cancer. In particular, the present application found that only the FAS gene is able to predict the prognosis of pancreatic cancer by its presence or absence of one of the mutations in table 2. Furthermore, in the present application, no correlation of other sequence mutations in FAS gene with pancreatic cancer prognosis was found in the earlier study.
In sum, through the probe detection of FAS gene mutation, the accurate prognosis situation prediction is carried out on patients with pancreatic duct adenocarcinoma, so that clinicians can comprehensively know the disease situation of the patients, assist in guiding the treatment decision of the clinicians, and play an important role in the treatment, prognosis evaluation and sanitation economics of the diseases.
The technical features of the above-described embodiments and examples may be combined in any suitable manner, and for brevity of description, all of the possible combinations of the technical features of the above-described embodiments and examples are not described, however, as long as there is no contradiction between the combinations of the technical features, they should be considered to be within the scope described in the present specification.
The above examples merely represent a few embodiments of the present invention, which facilitate a specific and detailed understanding of the technical solutions of the present invention, but are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention. Further, it is understood that various changes and modifications of the present invention may be made by those skilled in the art after reading the above teachings, and equivalents thereof fall within the scope of the present application. It should also be understood that, based on the technical solutions provided by the present invention, those skilled in the art obtain technical solutions through logical analysis, reasoning or limited experiments, all of which are within the scope of protection of the appended claims. The scope of the patent of the invention should therefore be determined with reference to the appended claims, which are to be construed as in accordance with the doctrines of claim interpretation.
Claims (4)
1. Application of reagent for detecting FAS gene mutation in preparing pancreatic duct adenocarcinoma prognosis detection product;
the mutation site is selected from g.8901119C > T or/and g.89021477G > A.
2. The use according to claim 1, wherein the reagent comprises a specific hybridization probe.
3. The use according to claim 2, wherein the specific hybridization probe targets an aRNA that binds to the FAS gene.
4. Use according to any one of claims 1 to 3, wherein the sample detected is a tissue or a cell.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211455595.0A CN116949176B (en) | 2022-11-21 | 2022-11-21 | Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211455595.0A CN116949176B (en) | 2022-11-21 | 2022-11-21 | Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116949176A CN116949176A (en) | 2023-10-27 |
CN116949176B true CN116949176B (en) | 2024-04-02 |
Family
ID=88447981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211455595.0A Active CN116949176B (en) | 2022-11-21 | 2022-11-21 | Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116949176B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114761111A (en) * | 2019-10-05 | 2022-07-15 | 使命生物公司 | Methods, systems, and devices for simultaneous detection of copy number variation and single nucleotide variation in single cells |
WO2022212558A1 (en) * | 2021-03-30 | 2022-10-06 | Genecentric Therapeutics, Inc. | Methods for assessing proliferation and anti-folate therapeutic response |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20130225433A1 (en) * | 2012-02-29 | 2013-08-29 | The Regents Of The Universitys Of Michagan | Prostate cancer markers and uses thereof |
-
2022
- 2022-11-21 CN CN202211455595.0A patent/CN116949176B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114761111A (en) * | 2019-10-05 | 2022-07-15 | 使命生物公司 | Methods, systems, and devices for simultaneous detection of copy number variation and single nucleotide variation in single cells |
WO2022212558A1 (en) * | 2021-03-30 | 2022-10-06 | Genecentric Therapeutics, Inc. | Methods for assessing proliferation and anti-folate therapeutic response |
Non-Patent Citations (5)
Title |
---|
CD44 SNPrs187115: A Novel Biomarker Signature that Predicts Survival in Resectable Pancreatic Ductal Adenocarcinoma;Giovanni Stracquadanio等;Clin Cancer Res;第22卷(第24期);6069-6077 * |
Fas and Fas ligand expression in pancreatic adenocarcinoma;Nat L Pernick等;Pancreas等;第25卷(第3期);e36-41 * |
Polymorphisms in promoter region of FAS and FASL gene and risk of gastric cardiac adenocarcinoma;Rong-Miao Zhou等;Journal Of Gastroenterology And Hepatology;第25卷(第3期);555-561 * |
凋亡相关基因Fas和FasL在胰腺癌组织中的表达;殷占新等;中华肿瘤防治杂志(第4期);283-286 * |
胸腺嘧啶-DNA糖基化酶TDG在胰腺癌中的表达调控及作用机制研究;孙杰;中国博士学位论文全文数据库医药卫生科技辑(第8期);E072-258 * |
Also Published As
Publication number | Publication date |
---|---|
CN116949176A (en) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Pinzani et al. | Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase–polymerase chain reaction results and feasibility of molecular analysis by laser microdissection | |
CN101454668A (en) | Methods for prediction and prognosis of cancer, and monitoring cancer therapy | |
CN105917008A (en) | Gene expression panel for prognosis of prostate cancer recurrence | |
US20230366034A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
WO2014160645A2 (en) | Neuroendocrine tumors | |
CN104745681A (en) | Multi-element generic composition and use thereof | |
CN115927608B (en) | Biomarkers, methods and diagnostic devices for predicting pancreatic cancer risk | |
CN110541030B (en) | Bladder cancer detection kit and application thereof | |
CN110229899B (en) | Plasma marker combinations for early diagnosis or prognosis prediction of colorectal cancer | |
CN108342478B (en) | Circulating tumor cell metabolism typing marker and application thereof | |
WO2011146937A1 (en) | Methods and kits useful in diagnosing nsclc | |
CN116949176B (en) | Application of reagent for detecting FAS gene mutation site in preparation of pancreatic duct adenocarcinoma prognosis detection product | |
CN116656811B (en) | Pancreatic duct adenocarcinoma prognosis detection kit and application thereof | |
CN110331207A (en) | Adenocarcinoma of lung biomarker and related application | |
CN113249479B (en) | Pancreatic cancer related lncRNA marker, probe and application of detection kit in pancreatic cancer diagnosis | |
CN115927614A (en) | Early intestinal cancer screening detection primer, detection method and kit based on Alu repeat element | |
CN114410795A (en) | Liver cancer early detection based on miRNA (micro ribonucleic acid) feature marker | |
CN113999914A (en) | Novel combined marker for early detection of multi-target hepatocellular carcinoma and application thereof | |
CN107326092A (en) | Applications and colorectal cancer detection kit of the related miRNA of colorectal cancer as biomarker | |
CN102409090A (en) | Nucleic acid detection probe, primers and kit for inhibitor of apoptosis protein Survivin gene, and detection method thereof | |
US20110236890A1 (en) | Method of screening for cancer by detecting mutations in the delta-catenin gene promoter and 5'-untranslated region | |
CN116144772B (en) | Application of Hsa_circ_0006117 in preparation of lung adenocarcinoma treatment drugs | |
CN114277136B (en) | Lung cancer gene marker based on ecDNA and application thereof | |
CN104024434B (en) | In-vitro diagnosis or the method for prognosis for carcinoma of prostate | |
CN109706146A (en) | Application of the finger-print of tiny RNA composition in the Cancerous Pleural Effusion diagnosing and treating of people |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |